MU Department of Medicine 2011-2013 Annual Report Feb. 2014

60 Annual Report University of Missouri- Columbia Hematology/medical oncology Cont. Co-Investigator Technical Principal Investigator Graduate Training in Shared Equipment Evaluation Radiopharmaceutical Chemistry, Program Request: Modular laboratory trastuzumab plus placebo versus National Institute of Biomedical Cassette Radiosynthesis System, chemotherapy plus trastuzumab plus Imaging and BioEngineering, $743,961, U.S. Department of Veterans pertuzumab as adjuvant therapy in 09/01/2007 to 08/31/2013 Affairs, $112,800, 06/01/2013 to 05/31/2014 patients with operable HER2-positive breast cancer, Mayo Clinic, $3,572, Co-Investigator 07/01/2012 to 06/30/2022 A Proposal for Fellowship Support Principal Investigator in the Area of Environmental/ Salary support award, U.S. Department Principal Investigator Environmental Health Engineering, U.S. of Veterans Affairs, $147,819, CT IV: International, Randomized, Department of Education, $936,324, 04/01/2013 to 03/31/2017 Double-Blind, Controlled Study of 09/01/2012 to 08/31/2015 Principal Investigator Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Co-Investigator Targeted Radiotherapy/Chemotherapy Diagnosed, Surgically Resected, Fellowship Support in the Area of Treatment of Prostate Cancer EGFRvIII-positive Glioblastoma, Nuclear Science and Engineering, U.S. (1I01BX001699-01A2), Department Novella, $1,632, 09/01/2012 to Department of Education, $936,324, of Veteran Affairs: Merit Review – 08/31/2015 09/01/2012 to 08/31/2015 Renewal, $648,346, 04/01/2013 to Principal Investigator Principal Investigator Cancer and Leukemia Group B Molecular Imaging of Cancer Using Principal Investigator Foundation, CALGB, $128,785, Tc-99m DMSA, Imagenomics, LLC, Collaboration with Lixin Ma, U.S. 01/01/1998 to 08/31/2020 $503,755, 03/01/2013 to 02/28/2016 Department of Veterans Affairs, $4,389, Principal Investigator Co-Investigator 07/01/2013 to 03/31/2014 Cancer & Leukemia Group B Clinical Role of mTOR-miR-29 A2R Axis in Trials, University of Chicago, Over-Nutrition Related Cardiovascular Key Personnel $914,051, 04/01/1995 to 03/31/2013 Diseases, National Institutes of The mTORCI miR29AT2R Axis in Health, $1,575,000, 04/01/2013 to Cardiovascular Diseases, National 03/31/2018 Institutes of Health, $355,141, 03/31/2017 Timothy Hoffman, PhD 07/03/2013 to 04/30/2014 Principal Investigator Shared Equipment Evaluation Director of VA BIC Program Request: Small Animal 7 University of Missouri – Office of the Tamara Hopkins, MD Tesla MRI Computer System Upgrade, Provost, VA Biomolecular Imaging Investigator U.S. Department of Veterans Affairs, Center Partnership Award, $1,500.000, A Randomized Discontinuation Study $403,000, 04/01/2011 to 03/31/2012 07/01/2003 to 06/30/2018 of XL184 in Subjects with Advanced Principal Investigator Technical Principal Investigator Research Career Scientist, U.S. Shared Equipment Research Program Department of Veterans Affairs, Request: Real Time Cell Analyzer Investigator $446,880, 10/01/2009 to 09/13/2014 (RTCA), Department of Veteran Affairs, Randomized, Double Blind, $52,000, 07/01/2012 to 12/01/2012 Phase 3 Trial to Compare the Solid Tumors, Exelixis, $3,026, 10/22/2009 to 10/21/2013 Efficacy of Ipilimumab vs Placebo Co-Investigator Phage Display for Improved Peptide- Technical Principal Investigator in Asymptomatic or Minimally based Tumor Targeting and Imaging Shared Equipment Evaluation Program Symptomatic Patients with Metastatic Agents, U.S. Department of Veterans Request: Odyssey CLx Infrared Imaging Chemotherapy-Naive Castration Affairs, $956,252, 04/01/2011 to System, U.S. Department of Veterans Resistant Prostate Cancer, Bristol 03/31/2015 Affairs, $58,200, 06/01/2013 to Myers Squibb, $2,689, 08/18/2010 to 05/31/2014 8/17/2012 Research Projects for Interrogations Technical Principal Investigator Investigator of Biological Systems: Training for the Shared Equipment Evaluation Program An Open-Label, Randomized, Phase Development of Novel Radiotracers, Request: Advion Expression LC-MS 3 Study of Inotuzumab Ozogamicin U.S. Department of Energy, $1,056,001, System, U.S. Department of Veterans Administered In Combination with 09/01/2011 to 08/31/2013 Affairs, $109,700, 06/01/2013 to Rituximab Compared to Defined 05/31/2014 Investigator’s Choice Therapy In Co-Investigator

MU Department of Medicine 2011-2013 Annual Report Feb. 2014 | Page 60